PharmaTelevision - BIA: Funding and the Future of Biotech

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: BIA: Funding and the Future of Biotech

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

Dr Fintan Walton talks with Clive Dix, Chairman, of the BioIndustry Association (BIA) at the BIA Leadership Summit in Hertfordshire.

Clive discusses:

• The state of play within the pharma and biotech industry today

• The new biotech market opening in the wake of the IPO market closing

• Importance of business angels for funding

• Government funding of research, and, in particular, the BIA’s role in the Office of Lifescience and the Government’s £150 million Innovation/Cornerstone Fund for the industry in the UK

• The future of the UK Biotech industry

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

The state of play within the pharma and biotech industry today.

Fintan Walton:

Hello and welcome to PharmaVentures business review here at the BioIndustry Association Leadership Summit here in Hertfordshire in the UK. On this show I have Clive Dix who is the Chairman of theBIA, which is the BioIndustry Association here in the UK. Welcome to the show.

Clive Dix:

Thank you.

Fintan Walton:

Clive Dix, as Chairman of BIA but also with somebody with a lot of experience in the pharmaceutical industry and particularly the biotech industry. How would you describe the state of play for biotech in the UK today?

Clive Dix:

I guess really it's kind of pretty tough and not because of the recession we were heading for a tough period anyway and it's one would be looking, looking at for long time.

Fintan Walton:

And when you describe it is tough you presumably mean at the financial level, is not because of the lack of invention or lack of resource, it's a lack of money?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Clive Dix

Chairman

Dr Clive Dixis the current Chairman of the BioIndustry Association (BIA) and Non-Executive Chairman of Modern Biosciences plc. Dr Clive Dix has more than 20 years' experience in Lifescience research, with over 15 years in senior pharmaceutical industry positions, and a degree and PhD in Pharmacology. Dr Clive Dix's expertise includes an in depth understanding of all facets of drug discovery and development, a broad knowledge of the science and commercial landscape of a variety of therapeutic areas, and solid experience of the pharmaceutical business and finance community supporting the sector. Dr Clive Dix was previously co-founder and Chief Executive of PowderMed Ltd, a vaccines development company acquired by Pfizer in November 2006. Prior to running PowderMed, Dr Clive Dix was Senior Vice President, Research and Development and a Board member of PowderJect Pharmaceuticals plc until its acquisition by Chiron Vaccines in 2003. Dr Clive Dix began his career in industry at Ciba-Geigy and then GlaxoWellcome, where he left as UK Research Director in 2001.

BioIndustry Association

The BioIndustry Association (BIA) is the trade association for innovative enterprises in the UK 's bioscience sector. Established in 1989, its mission is to ?encourage and promote a thriving, financially sound sector of the UK economy, built upon developments across the biosciences.? The BIA seeks to create economic growth, increase employment opportunities, and expand the skills base.